Skip to main content
. 2021 Mar 6;9(3):230. doi: 10.3390/vaccines9030230

Figure 2.

Figure 2

Development of infection with PRV-1, -2 and -3. Levels of PRV-1 (A), PRV-2 (B) and PRV-3 (C) as detected in spleen with specific RT-qPCR assays targeting the S1 genome segment in the respective viruses and trial groups. The figures show individual Ct values and median (line) at each sampling from 2 to 18 weeks post injection (wpi). Gray dots show virus levels in naïve cohabitants added to the tank at 5 wpi and removed at 10 wpi (5 weeks after exposure). Relative levels of PRV-1, -2 and -3 in heart at 15 and 18 weeks post infection (D).